09/02/2026
Today, uniQure announced it has submitted a Biologics License Application, or BLA, to the FDA for AMT-130, an investigational gene therapy for Huntington's disease. A BLA is the formal request a company files asking the FDA to review a treatment for approval. They also submitted an application to UK regulators.
This is a real milestone after a long road, and we know our community has followed every twist and turn of this program. While this application stands on promising data from a small number of people, the FDA still has to review everything carefully, and it will be some time before we know the outcome. HDSA will keep you posted as it unfolds.
Visit:https://hdsa.org/wp-content/uploads/2026/09/uniQure-Announces-Submission-of-Biologics-License-Application-for-Ifezuntirgene-Inilparvovec-AMT-130-in-Huntingtons-Disease.pdf for more information.